AZ invests in RNA company

Thursday 23 September 2021

United Kingdom

AstraZeneca Plc has invested in a UK university spin-out that has a platform for developing vaccines and medicines using self-amplifying RNA. The company, VaxEquity Ltd, was founded in 2020 by Robin Shattock, head of immunology of infection at Imperial College London and Morningside Ventures, a Chinese venture capital and private equity group. Both Morningside and AstraZeneca have made equity investments in the company, the sizes of which were not disclosed.